Impact of specialty drugs on the use of other medical services

Geoffrey F. Joyce, Dana P. Goldman, Pinar Karaca-Mandic, Grant D. Lawless

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Objective: To examine whether initiation of a biologic agent to treat 2 autoimmune disorders - rheumatoid arthritis (RA) and multiple sclerosis (MS)-affects use of other medical services. Study Design: Longitudinal analysis from 1997 to 2005 examining linked pharmacy and medical claims from large, private employers. Methods: The study sample included 30,761 individuals newly diagnosed with RA (92,660 person-years) and 8961 unique individuals with MS (25,100 person-years). Negative binomial models were used to estimate changes in inpatient, outpatient, and procedure use before and after initiating a biologic drug for each condition. Results: Starting a biologic response modifier was associated with a reduction in physician visits and use of expensive procedures for patients with RA within 2 to 3 years of initiation. Use of immunomodulatory therapy for MS was associated with a reduced number of hospitalizations and expensive procedures within 2 years of initiation. Although biologics may reduce other types of service use, the savings do not come close to offsetting the full cost of these drugs. Conclusions: Given the high cost of many specialty drugs, health plans may rightly focus on making sure only patients who will most benefit receive them. But once such patients are identified, it makes little sense to limit coverage.

Original languageEnglish (US)
Pages (from-to)821-828
Number of pages8
JournalAmerican Journal of Managed Care
Volume14
Issue number12
StatePublished - Dec 1 2008

Fingerprint

Multiple Sclerosis
Rheumatoid Arthritis
Pharmaceutical Preparations
Drug Costs
Immunomodulation
Biological Factors
Statistical Models
Biological Products
Longitudinal Studies
Inpatients
Hospitalization
Outpatients
Physicians
Costs and Cost Analysis
Health

Cite this

Joyce, G. F., Goldman, D. P., Karaca-Mandic, P., & Lawless, G. D. (2008). Impact of specialty drugs on the use of other medical services. American Journal of Managed Care, 14(12), 821-828.

Impact of specialty drugs on the use of other medical services. / Joyce, Geoffrey F.; Goldman, Dana P.; Karaca-Mandic, Pinar; Lawless, Grant D.

In: American Journal of Managed Care, Vol. 14, No. 12, 01.12.2008, p. 821-828.

Research output: Contribution to journalArticle

Joyce, GF, Goldman, DP, Karaca-Mandic, P & Lawless, GD 2008, 'Impact of specialty drugs on the use of other medical services', American Journal of Managed Care, vol. 14, no. 12, pp. 821-828.
Joyce, Geoffrey F. ; Goldman, Dana P. ; Karaca-Mandic, Pinar ; Lawless, Grant D. / Impact of specialty drugs on the use of other medical services. In: American Journal of Managed Care. 2008 ; Vol. 14, No. 12. pp. 821-828.
@article{a22af7bcaf7c4f5d8dbe63f398bd5c02,
title = "Impact of specialty drugs on the use of other medical services",
abstract = "Objective: To examine whether initiation of a biologic agent to treat 2 autoimmune disorders - rheumatoid arthritis (RA) and multiple sclerosis (MS)-affects use of other medical services. Study Design: Longitudinal analysis from 1997 to 2005 examining linked pharmacy and medical claims from large, private employers. Methods: The study sample included 30,761 individuals newly diagnosed with RA (92,660 person-years) and 8961 unique individuals with MS (25,100 person-years). Negative binomial models were used to estimate changes in inpatient, outpatient, and procedure use before and after initiating a biologic drug for each condition. Results: Starting a biologic response modifier was associated with a reduction in physician visits and use of expensive procedures for patients with RA within 2 to 3 years of initiation. Use of immunomodulatory therapy for MS was associated with a reduced number of hospitalizations and expensive procedures within 2 years of initiation. Although biologics may reduce other types of service use, the savings do not come close to offsetting the full cost of these drugs. Conclusions: Given the high cost of many specialty drugs, health plans may rightly focus on making sure only patients who will most benefit receive them. But once such patients are identified, it makes little sense to limit coverage.",
author = "Joyce, {Geoffrey F.} and Goldman, {Dana P.} and Pinar Karaca-Mandic and Lawless, {Grant D.}",
year = "2008",
month = "12",
day = "1",
language = "English (US)",
volume = "14",
pages = "821--828",
journal = "American Journal of Managed Care",
issn = "1088-0224",
publisher = "Ascend Media",
number = "12",

}

TY - JOUR

T1 - Impact of specialty drugs on the use of other medical services

AU - Joyce, Geoffrey F.

AU - Goldman, Dana P.

AU - Karaca-Mandic, Pinar

AU - Lawless, Grant D.

PY - 2008/12/1

Y1 - 2008/12/1

N2 - Objective: To examine whether initiation of a biologic agent to treat 2 autoimmune disorders - rheumatoid arthritis (RA) and multiple sclerosis (MS)-affects use of other medical services. Study Design: Longitudinal analysis from 1997 to 2005 examining linked pharmacy and medical claims from large, private employers. Methods: The study sample included 30,761 individuals newly diagnosed with RA (92,660 person-years) and 8961 unique individuals with MS (25,100 person-years). Negative binomial models were used to estimate changes in inpatient, outpatient, and procedure use before and after initiating a biologic drug for each condition. Results: Starting a biologic response modifier was associated with a reduction in physician visits and use of expensive procedures for patients with RA within 2 to 3 years of initiation. Use of immunomodulatory therapy for MS was associated with a reduced number of hospitalizations and expensive procedures within 2 years of initiation. Although biologics may reduce other types of service use, the savings do not come close to offsetting the full cost of these drugs. Conclusions: Given the high cost of many specialty drugs, health plans may rightly focus on making sure only patients who will most benefit receive them. But once such patients are identified, it makes little sense to limit coverage.

AB - Objective: To examine whether initiation of a biologic agent to treat 2 autoimmune disorders - rheumatoid arthritis (RA) and multiple sclerosis (MS)-affects use of other medical services. Study Design: Longitudinal analysis from 1997 to 2005 examining linked pharmacy and medical claims from large, private employers. Methods: The study sample included 30,761 individuals newly diagnosed with RA (92,660 person-years) and 8961 unique individuals with MS (25,100 person-years). Negative binomial models were used to estimate changes in inpatient, outpatient, and procedure use before and after initiating a biologic drug for each condition. Results: Starting a biologic response modifier was associated with a reduction in physician visits and use of expensive procedures for patients with RA within 2 to 3 years of initiation. Use of immunomodulatory therapy for MS was associated with a reduced number of hospitalizations and expensive procedures within 2 years of initiation. Although biologics may reduce other types of service use, the savings do not come close to offsetting the full cost of these drugs. Conclusions: Given the high cost of many specialty drugs, health plans may rightly focus on making sure only patients who will most benefit receive them. But once such patients are identified, it makes little sense to limit coverage.

UR - http://www.scopus.com/inward/record.url?scp=58149091493&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149091493&partnerID=8YFLogxK

M3 - Article

C2 - 19067499

AN - SCOPUS:58149091493

VL - 14

SP - 821

EP - 828

JO - American Journal of Managed Care

JF - American Journal of Managed Care

SN - 1088-0224

IS - 12

ER -